SB497115

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Hepatitis CHepatitis C, ChronicPurpura, Thrombocytopaenic, IdiopathicThrombocytopaeniaThrombocytopenia

Phase 2

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)

CompletedNCT00102739

GlaxoSmithKlinePurpura, Thrombocytopaenic, Idiopathic

Start: 2005-02-28End: 2007-01-31Updated: 2013-04-15

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy

CompletedNCT00102726

GlaxoSmithKlineThrombocytopaenia

Start: 2005-02-28End: 2007-02-28Updated: 2017-03-23

SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C

CompletedNCT00110799

GlaxoSmithKlineHepatitis C, Hepatitis C, Chronic, Thrombocytopenia

Start: 2005-04-30End: 2006-11-30Updated: 2012-06-04

Related Papers

A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors.

2010-10-0144 citations

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.

2009-02-01378 citations

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

2007-11-01536 citations

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.

2007-11-01302 citations